CELGENE CORP /DE/
S-4/A, EX-23.3, 2000-08-09
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: CELGENE CORP /DE/, S-4/A, EX-23.1, 2000-08-09
Next: CELGENE CORP /DE/, S-4/A, EX-23.4, 2000-08-09





                                                                    EXHIBIT 23.3

                      [LETTERHEAD OF PENNIE & EDMONDS LLP]


                                 August 7, 2000


Mr. Joseph J. Day, Jr.
Senior Vice President
Planning and Business Development
Celgene Corporation
7 Powder Horn Drive
Warren, NJ 07059


     Re: S-4 Registration Statement


Dear Mr. Day:

         We  consent  to  the  following reference to our firm under the heading
"Experts" in the S-4 Registration Statement ("Prospectus"):

       --The  statements  in  this  Prospectus  that  relate to thalidomide U.S.
       patent   rights   licensed   from   The   Rockefeller   University   and
       EntreMed/Children's  Medical  Center  Corporation under the caption "Risk
       Factors--The   combined   company   may   not  be  able  to  protect  its
       intellectual  property"  have  been  reviewed  and  approved  by Pennie &
       Edmonds  LLP  as  special patent counsel to Celgene Corporation for these
       matters,  and  are  included  herein  in  reliance  upon their review and
       approval as experts in the United State Patent Law.--


                                        Very truly yours,


                                        /s/ Pennie & Edmonds LLP
                                        Pennie & Edmonds LLP


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission